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ABSTRACT Extracellular senile plaques are a central pathological feature of Alzheimer’s disease. At the core of these plaques
are ﬁbrillar deposits of b-amyloid peptide (Ab). In vitro, Ab spontaneously assembles into amyloid ﬁbrils of cross-b sheet
structure. Although it was once believed that the ﬁbrils themselves were toxic, more recent data supports the hypothesis that
aggregation intermediates, rather than fully formed ﬁbrils, are the most damaging to neuronal tissue. In previously published
work, we identiﬁed several small peptides that interact with Ab and increase its aggregation rate while decreasing its toxicity. In
this work, we examined in detail the interaction between Ab and one of these peptides. Using a mathematical model of Ab
aggregation kinetics, we show that the dominant effect of the peptide is to accelerate lateral association of Ab ﬁlaments into ﬁbrils.
INTRODUCTION
Alzheimer’s disease (AD) is an age-associated neurodegen-
erative disease characterized by loss of memory and language
skills, damaged cognitive function, and altered behavior. A
central pathological feature of AD is the presence of ex-
tracellular senile plaques, found in the hippocampus and the
neocortex and associated with synaptic loss and cell death
(Selkoe, 1991). At the core of senile plaques are protein-
aceous amyloid deposits. Chemical analysis of these deposits
revealed that the major protein constituent is b-amyloid
(Ab) (Glenner and Wong, 1984; Masters et al., 1985). Ab is
a 39–43 residue proteolytic fragment of a larger integral
membrane protein called amyloid precursor protein (APP)
(Kang et al., 1987).
Ab undergoes aggregation spontaneously and assembles
into amyloid ﬁbrils with a cross b-sheet structure (Kirschner
et al., 1987). Ab assembly can be accelerated by several
factors, including locally high Ab concentration, acidic pH,
metal ions, osmolytes, and interaction with lipid membranes
(Barrow and Zagorski, 1991; Hilbich et al., 1991; Fraser
et al., 1992; Yang et al., 1999; Yip et al., 2002; for review see
McLaurin et al., 2000). Electron microscopy (EM) studies
demonstrated that Ab ﬁbrils from senile plaques are straight
and unbranched, 5–12 nm in diameter, and appear to be in
a helical array of b-sheet structure (Burkoth et al., 2000; for
review see Serpell, 2000).
Multiple observations indicate that amyloid ﬁbril forma-
tion is an early and required event in the AD neurodegener-
ative process (Pike et al., 1993; Selkoe, 1993; Simmons et al.,
1994; Moran et al., 1995; Geula et al., 1998). The ‘‘amyloid
cascade’’ hypothesis for AD postulates that amyloid ﬁbril
accumulation directly leads to synaptic loss, neuritic
dystrophy, and the neurotransmitter deﬁcits that are mani-
festations of dementia (Hardy and Higgins, 1992). However,
more recent in vitro observations have demonstrated that
small, soluble, and diffusible oligomeric Ab species are also
capable of initiating pathogenic events (Roher et al., 1996;
Lambert et al., 1998; Hartley et al., 1999). These data have
motivated several researchers to postulate that Ab oligomeric
intermediates, rather than fully formed ﬁbrils, are the pre-
dominant toxic species (Kirkitadze et al., 2002).
Considerable research effort has focused on discovery of
candidate compounds that block the toxicity of Ab, by
targeting a speciﬁc step involved in Ab aggregation
(Camilleri et al., 1994; Tomiyama et al., 1994; Klunk et al.,
1998; Pappolla et al., 1998; Hughes et al., 2000). Given the
hypothesis that aggregation intermediates are responsible for
Ab toxicity, such compounds could theoretically prevent all
aggregation, or alternatively cause further association of toxic
oligomers into larger nontoxic aggregates. In previous work
from our group, a strategy for designing peptidyl inhibitors
against Ab toxicity was proposed (Pallitto et al., 1999; Lowe
et al., 2001). Brieﬂy, the inhibitors were envisioned as
containing a ‘‘recognition domain,’’ a short peptide sequence
homologous to a fragment of full-length Ab (KLVFF, 16–
20), and a ‘‘disrupting domain,’’ a polypeptide chain with the
ability to interfere with Ab aggregation. Inhibitors that
protected PC-12 cells from Ab toxicity actually increased the
rate of Ab aggregation (Pallitto et al., 1999; Lowe et al.,
2001). Among these peptides, KLVFFK6was the most potent
at preventing Ab-associated toxicity to PC-12 cells and
caused the largest change in Ab aggregation kinetics and
aggregate morphology (Pallitto et al., 1999).
In previous work, we developed a mathematical model of
Ab aggregation kinetics from in vitro experimental data
(Pallitto and Murphy, 2001). In this article, we carefully
evaluated Ab aggregation kinetics in the presence of
KLVFFK6. Several questions we addressed include: 1), Does
the inhibitor change the distribution of Ab between non-
amyloid and amyloid pathways? 2),Which speciﬁc step in the
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Ab aggregation pathway is the most affected by KLVFFK6?
3), What is the mechanism of interaction between Ab and
inhibitors? To answer these questions, physicochemical




Ab(1–40) was purchased from AnaSpec (San Jose, CA). KLVFFK6 was
synthesized by solid phase peptide synthesis using Fmoc-protected amino
acids and puriﬁed by reverse phase high-pressure liquid chromatography on
a C4 column (Vydac, Hesperia, CA) using linear gradient of acetonitrile/
water with 0.1% triﬂuoroacetic acid. Molecular mass of KLVFFK6 was
analyzed by mass spectrometry to be 1421.7 Da (theoretical molecular mass
of 1421.9 Da). Peptides were stored as lyophilized powders at 70C.
Sample preparation
Phosphate-buffered saline with azide ((PBSA) 0.01 M Na2HPO4/NaH2PO4,
0.15 M NaCl, 0.02% (w/v) NaN3, pH 7.4) was double ﬁltered through 0.22-
mm ﬁlters. Urea (8 M) was prepared in 10 mM glycine-NaOH buffer, pH 10,
then ﬁltered through 0.22-mm ﬁlters. Lyophilized Ab(1–40) was solubilized
at a concentration of 2.8 mM using preﬁltered 8M urea, pH 10. After 10 min,
samples were diluted to 140 mMAb into ﬁltered PBSA, or PBSA containing
KLVFFK6. Samples were rapidly ﬁltered through 0.45-mm ﬁlters directly
into light-scattering cuvettes (for light scattering (LS)) or microtubes (for size
exclusion chromatography (SEC)). Molecular-biology-grade urea was
purchased from Boehringer-Mannheim (Indianapolis, IN). All other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO). The con-
centration of Ab was determined from the peak area of the sample injected
onto the fast protein liquid chromatography system without the column in
place, using an extinction coefﬁcient of 0.3062 (mg/ml)1 cm1 (Pallitto and
Murphy, 2001), and was 120 6 20 mM. Residual urea was 0.4 M. Urea
dissolution was required to yield highly quantitatively reproducible results
and to ensure a controlled initial state. The urea may change absolute rates of
aggregation, but does not change trends (Lowe et al., 2001).
Size exclusion chromatography
Samples were analyzed with SEC using a precision column prepacked with
Superdex 75 (Pharmacia, Piscataway, NJ) on a Pharmacia fast protein liquid
chromatography system, as described previously (Pallitto and Murphy,
2001). Brieﬂy, the mobile phase ﬂow rate was set at 0.05 ml/min and elution
peaks were detected by ultraviolet (UV) absorbance at either 214 or 280 nm.
Mobile phase buffer was matched to buffer used for dissolution of Ab. The
column was calibrated using the following proteins as molecular weight
standards: insulin chain B (3500), ubiquitin (8500), ribonuclease A (13,700),
ovalbumin (43,000), and bovine serum albumin (67,000). To determine the
distribution between small oligomers that could be resolved on the column
(molecular mass 3–70 kDa), and larger species that could not be resolved,
samples were injected without the column in place; the percent of non-
aggregates (monomer and dimer (M1D)) was calculated by dividing the
M1D peak area by the peak area without the column in place.
Laser light scattering
Samples prepared as described above were placed in a bath of the index-
matching solvent decahydronaphthalene, which was temperature controlled
to 25C. Dynamic light scattering data were taken using a Coherent (Santa
Clara, CA) argon ion laser operated at 488 nm and a Malvern 4700c system
(Southborough, MA), as described in more detail elsewhere (Lowe et al.,
2001).
Information on average particle molecular mass, shape, and dimensions
were obtained using static light scattering measurements, as described
previously in detail (Murphy and Pallitto, 2000). Two alternative models of
particle shape, semiﬂexible (wormlike) chain and semiﬂexible branched,
were used to ﬁt the data. The semiﬂexible chain model describes a linear
chain with total contour length Lc and Kuhn statistical segment length lk (a
measure of the stiffness of the chain, equal to two times the persistence
length). We have shown previously that this model is a good description of
Ab ﬁbrils (Shen et al., 1993; Shen and Murphy, 1995). The continuous
semiﬂexible branchedmodel describes a branched particle with a center from
which extend nb (number of branches) semiﬂexible chains of contour length
Lc,a and stiffness lk.
Circular dichroism spectroscopy
Secondary structure of Ab was determined using circular dichroism (CD),
collected using an Aviv 62ADS circular spectrometer (Lakewood, NJ) in the
far-UV range with 0.1 cm of pathlength of cuvette. Ellipticity of sample
containing 140 mM of Ab with and without addition of KLVFFK6 at each
wavelength was measuredwithout dilution for 5 s and then averaged out. The
lower wavelength boundary was limited to 211 nm due to the residual urea
(0.4 M) in the sample. The spectrum of the background was measured for
5 s and averaged, followed by that of the sample. The average background
was then subtracted from the average sample spectrum. The percent of
each secondary structure element was calculated by nonlinear least square
curve ﬁtting of experimental ellipticities using several standard methods
(Provencher and Glo¨ckner, 1981; Manavalan and Johnson, 1987).
Mathematical modeling
Amathematical model of Ab aggregation kinetics was developed by Pallitto
and Murphy (2001). A schematic of the model is shown in Fig. 1. Diameters
of ﬁlament and ﬁbril were assumed to be 3 and 8 nm, respectively. Model
equations were solved numerically, and parameter values were obtained by
multiresponse nonlinear regression, as described previously (Pallitto and
Murphy, 2001).
RESULTS
To allow for a more rigorous analysis of Ab kinetics, 8 M
urea/pH 10 was used to completely dissolve Ab and render
it monomeric and random coil before dilution into PBSA
to initiate aggregation (Pallitto and Murphy, 2001). A
mathematical model describing the kinetics of assembly
was developed previously (Pallitto and Murphy, 2001). A
schematic of the model is shown in Fig. 1. Brieﬂy, denatured
monomersMu rapidly refolded into either stable monomerM
or dimer D, or less stable dimeric intermediate I. I co-
operatively assembled to nucleus N to initiate formation of
thin ﬁlaments f. Filaments grew linearly by repeated addition
of I. Cooperative lateral association of ﬁlaments resulted in
formation of ﬁbrils F. F elongated by end-to-end association.
The kinetic model was in good agreement with SEC and LS
experiments.
KLVFFK6 protected PC-12 cells from Ab-associated
toxicity while signiﬁcantly accelerating Ab aggregation
(Pallitto et al., 1999). In those experiments, Abwas dissolved
in 0.1% triﬂuoroacetic acid before dilution into PBSA
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containing test inhibitory peptide. In the work presented here,
we used the mathematical model to evaluate the mechanism
underlying the effect of KLVFFK6 on aggregation kinetics of
Ab, starting from the urea-unfolded state. Points of interest
include: a), alteration of secondary structure of Ab; b),
change in initial M1D and I split; c), shift of Ab nucleation/
elongation balance; d), acceleration/deceleration of ﬁlament
assembly to ﬁbril; and e), extent of incorporation of
KLVFFK6 into Ab.
Effect of KLVFFK6 on Ab secondary structure
Ab aggregation is linked to conversion of the peptide from
random coil to b-sheet secondary structure. Ab in 8 M urea/
pH 10 is random coil, but after dilution into PBSA, Ab
spontaneously aggregates into b-sheet ﬁbrils. We evaluated
whether KLVFFK6 increased the extent of b-sheet structure.
Circular dichroism spectra were taken on samples containing
140 mM Ab and varying concentrations of KLVFFK6 (0:1,
0.1:1, 0.5:1, and 1:1 KLVFFK6:Ab molar ratio). KLVFFK6
alone was random coil (Fig. 2). KLVFFK6 did not alter CD
spectrum of Ab at any concentration, indicating no dis-
turbance of secondary structure by KLVFFK6 (Fig. 2). De-
convolution of CD spectra revealed ;35% of b-sheet
structure regardless of presence or absence of KLVFFK6.
Effect of KLVFFK6 on Ab population
Dilution of Ab from urea into PBSA produces a distribution
of variously sized species. Under our experimental con-
ditions, ;63% of total Ab was present as stable Ab
monomer or dimer, whereas the remainder was aggregates
of .70 kDa, consistent with previous reports (Pallitto and
Murphy, 2001). Size exclusion chromatography experiments
were performed to see whether KLVFFK6 changed the
distribution of Ab species between nonamyloidogenic and
FIGURE 1 A schematic showing Ab aggregation
kinetic model (Pallitto and Murphy, 2001).
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amyloidogenic states. Detection was set at 280 nm, at which
wavelength Ab, but not KLVFFK6, is detected. Percentages
of Abmonomer or dimer and aggregates were calculated and
compared to Ab alone (Table 1). Ab population was not
affected by KLVFFK6, and the distribution did not change
over time (data not shown).
Incorporation of KLVFFK6 into Ab
If KLVFFK6 bound to Ab monomers and dimers, one might
expect a shift in elution time of the M1D peak caused by
a molecular mass increase. No such shift was observed in the
presence of KLVFFK6 (data not shown). This result indicates
that KLVFFK6 is not associated to any measurable extent
with monomeric or dimeric Ab species. We repeated SEC
analysis of Ab1KLVFFK6 with detection at 214 nm, where
both Ab and KLVFFK6 contributes to absorbance. We ob-
served a signiﬁcant peak at 39min elution time, matching that
of KLVFFK6 alone (data not shown). Comparison of the area
of this peak in the absence and presence of Ab suggested
most (.90%) of KLVFFK6 eluted as free peptide, although
accurate quantiﬁcation was not possible due to low signal/
noise ratio. This result implied very little of KLVFFK6 is
incorporated into aggregated Ab.
Effect of KLVFFK6 on Ab aggregation kinetics
We evaluated Ab aggregation kinetics in the presence of
varying concentrations of KLVFFK6 using light scattering.
Data are reported as average hydrodynamic diameter, dsph
and scattering intensity at 90 angle, Is(90), versus time.
Because small species contribute less to scattered light, dsph
and Is(90) indicate primarily the change in size and/or mass
of aggregates rather than of AbM1D. The rate of increase in
dsph and Is(90) increased, with increasing amounts of
KLVFFK6. The increase in Is(90) was approximately
twofold greater than the increase in dsph (Fig. 3). Because
Is(90) scales approximately with average aggregate molec-
ular mass, whereas dsph scales approximately with average
aggregate length, these results indicate that KLVFFK6
increased the linear density (mass per unit length) of Ab
aggregates.
Effect of KLVFFK6 on Ab aggregate
size and shape
We wondered whether the morphology of Ab aggregates
changed in the presence of KLVFFK6. To determine this, we
collected static light scattering data at multiple angles; results
are presented as a Kratky plot (Fig. 4). For Ab alone and
KLVFFK6 1 Ab (1:1 molar ratio), the Kratky plots were
fairly linear, characteristic of a rodlike morphology. With
increasing concentration of KLVFFK6, a shift of the ag-
gregate morphology was apparent. At 2.5:1 molar ratio, a
plateau at higher angles was observed, indicative of longer
ﬁbrils and a linear semiﬂexible chain morphology. At 5:1 and
10:1 molar ratio, there was a substantial change in the curve,
exhibiting an intermediate ‘‘bump’’ that is characteristic of
a branched morphology.
ÆMæw, Lc (or Lc,a), lk, and nb were determined by ﬁtting the
data to model equations for the appropriate particle structure
function. Results are summarized in Table 2. Both ÆMæw and
Lc increased with increasing concentration of KLVFFK6,
with a greater increase in ÆMæw than Lc. The increase in ÆMæw/
Lc implies greater average linear density with increasing
concentration of KLVFFK6, consistent with results shown in
Fig. 3.
FIGURE 2 Circular dichroism (CD) spectra of 140 mM of KLVFFK6
alone (thick solid line), Ab alone (thin solid line), and KLVFFK6 1 Ab at
1:1 (dashed line). Data for the other molar ratio of KLVFFK6:Ab we tested
were indistinguishable from those for Ab alone and 1:1 ratio of KLVFFK6
1 Ab (data not shown). All samples contained 140 mM of Ab and were
incubated for ;18–20 h before CD measurements. For a given wavelength,
data were collected for 5 s and averaged out. Due to residual urea, the
minimum wavelength was limited to 211–212 nm.
TABLE 1 Effect of KLVFFK6 on Ab population
Ab alone* KLVFFK6 1 Ab
y
% of aggregates (.70 kDa)z 37 6 8 38 6 4
% of nonaggregates (M 1 D)z 63 6 8 62 6 4
*Sample contained 140 mM of Ab.
ySample contained 140 mM of KLVFFK6 and 140 mM of Ab.
zThe identical samples were injected using the same sample loop and
detector with and without the column in place. To calculate the fraction of
Ab in monomer and dimer populations, the individual peak areas (obtained
with the column in place) were divided by the peak area without the
column. The fraction of aggregates (.70 kDa) was calculated by
difference. All values are mean 6 SD of six independently prepared
samples.
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Kinetic model of Ab aggregation in the
presence of KLVFFK6
Data were analyzed based on the kinetic model developed
previously (Pallitto and Murphy, 2001). SEC and CD data
indicated that KLVFFK6 does not change the split between
amyloidogenic and nonamyloidogenic Ab, implying no
change in the ‘‘refolding’’ step; this is reﬂected in the model
as no change inKMD, kM/kI, and kD/kI (Fig. 1). KLVFFK6 did,
however, strongly affect kinetics of growth in a concentration-
dependent manner. Therefore, the major change is down-
stream of the ‘‘refolding’’ step (Fig. 1). Light scattering data
were used to obtain the best ﬁt parameter values for ﬁlament
initiation and elongation (kp/kn), and ﬁbril formation by lateral
association (kla) and ﬁbril growth by end-to-end association
(dvﬁb) (Fig. 1). Because the kinetic model assumes a linear
aggregate morphology, kinetic data of samples exhibiting a
branchedmorphology could not be ﬁtted to themodel. For 5:1
ratio of KLVFFK6:Ab, it was not possible to obtain ﬁts if the
entire data set was used; therefore we used only data up to;4
h to evaluate parameters. For the same reason, no attempt was
made to ﬁt any of the data for 10-fold excess of KLVFFK6.
Our kinetic model captured growth of Ab in the presence
of KLVFFK6 reasonably well (Fig. 5). Parameter values are
summarized in Table 3. First, we examined the effect of
KLVFFK6 on ﬁlament initiation and elongation. kn and kp are
rate constants governing nucleus N initiation from unstable
intermediate species I, and ﬁlament initiation and growth by
addition of I, respectively. Therefore, kn/kp represents the
balance between new ﬁlament formation versus growth of
existing ﬁlaments. kn/kp was not substantially affected by
KLVFFK6, indicating that the peptide did not disturb this
balance. Then, we examined the effect of KLVFFK6 on ﬁbril
formation and growth. kla characterizes the rate of lateral as-
sociation of ﬁlaments into ﬁbrils, whereas dvﬁb characterizes
the rate of growth by ﬁbril end-to-end association. dvﬁb
decreased moderately in the presence of KLVFFK6. By far
the greatest effect of KLVFFK6 was on lateral association of
ﬁlaments into ﬁbrils: kla increased by approximately fourfold
at 1:10 ratio of KLVFFK6:Ab, ;70-fold at 1:1 ratio, and
;300-fold at 2.5:1 ratio.
DISCUSSION
Examination of the events by which monomeric Ab
associates into oligomers and ﬁbrils is of central importance
to elucidation of the molecular mechanisms underlying AD
pathogenesis. The fact that ﬁbrils formed in vitro are identical
FIGURE 3 Hydrodynamic diameter
dsph (A and B) and scattering intensity
at 90 angle Is(90) (C and D) for Ab
alone (s), KLVFFK61 Ab (1:10) (d),
(1:1) (n), (2.5:1) (:), (5:1) (h), and
(10:1) (n). All samples contained 140
mM Ab.
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to those in vivo as determined by EM and x-ray diffraction,
and are toxic to neuron cells, gives a strong justiﬁcation for
the validity of in vitro Ab aggregation studies (Kirschner
et al., 1987; Pike et al., 1993).
Peptides designed to interfere with Ab aggregation also
inhibited Ab-associated toxicity (Pallitto et al., 1999; Lowe
et al., 2001). Among these peptides, KLVFFK6 was judged
one of the most active. A detailed mathematical model of Ab
aggregation kinetics was previously proposed (Pallitto and
Murphy, 2001), and we hypothesized that the model could be
used to determine the speciﬁc step(s) in the aggregation
pathway affected by KLVFFK6.
We considered it possible that KLVFFK6 could increase
the Ab aggregation rate by changing the secondary structure
or the fraction of Ab that is aggregated. However, analysis of
CD spectra demonstrated that KLVFFK6 did not change the
b-sheet content of Ab preparations. From SEC analysis, we
observed no disturbance of the distribution of Ab between
M1D versus aggregated material. Furthermore, KLVFFK6
does not appear to bind measurably to M1D Ab (data not
shown). Together these results demonstrate that KLVFFK6
does not act by associating with monomeric Ab, by changing
Ab secondary structure, or by affecting the split of Ab
between nonamyloidogenic and amyloidogenic species
(Fig. 1). Thus, its action is felt in a later step in the aggre-
gation pathway.
Light-scattering analysis indicated that KLVFFK6 does
cause an increase in the rate of growth of aggregate size, as
measured by both dsph and Is(90). The change in Is(90) was
greater than the change in dsph, indicating that the increase in
growth rate of the average molar mass of the aggregates was
greater than the increase in growth rate of the average
aggregate length. Closer analysis of the angular dependence
of scattering showed that increasing the concentration of
KLVFFK6 increased the average molar mass and contour
length of the aggregates, and led to changes in morphology
from rigid rod to semiﬂexible chain to branched structures
(Table 2 and Fig. 4). A greater mass per unit length in the
presence of KLVFFK6 was detected, consistent with ob-
servations from the ﬁxed-angle scattering measurements.
The data were used to determine kinetic parameters in our
model. Neither the balance between ﬁlament elongation
versus initiation (kp/kn) nor end-to-end ﬁbril growth (dvﬁb)
were affected much (Table 3). Rather, the major effect of
KLVFFK6 was to accelerate the rate of lateral association of
ﬁlaments to ﬁbrils, as evidenced by a large and dose-
dependent increase in kla. This ﬁnding is consistent with
previous qualitative observations of an increase in linear
FIGURE 4 Effect of KLVFFK6 on scattering intensity of Ab aggregates.
Data are presented in the form of Kratky plots. Data were collected 21 h after
sample preparation for Ab alone (s), KLVFFK6 1 Ab (1:1) (n), (2.5:1)
(:), and (5:1) (h) or after 2 h for KLVFFK61 Ab (10:1) (n). Each sample
contained 140 mMAb. Lines indicate the ﬁtted particle shape function, P(q)
for semiﬂexible chains (s, n, and :) or a branched structure (h and n).
Kratky plot analysis of 10:1 sample after 21 h could not be made due to
formation of signiﬁcant amount of precipitates. c is the peptide con-
centration. q ¼ 4pn/l0 sin (u/2), where n is the refractive index of the
solvent, l0 is the wavelength of the incident beam in vacuo, and u is
the scattering angle. R is the Rayleigh ratio of sample. K ¼
4p2n2ðdn=dcÞ2=NAl40, where dn/dc is the refractive index increment, and
NA is Avogadro’s number.
TABLE 2 Size characteristics of Ab aggregates in the presence of KLVFFK6
Molar ratio (KLVFFK6:Ab)*
0:1y 1:1y 2.5:1y 5:1y 10:1z
ÆMæw (kDa) 190 6 20 700 6 20 4200 6 200 57,000 6 12,000 58,000 6 9000
Lc (or Lc,a) (nm) 90 6 5 160 6 5 830 6 30 1500 6 500 1400 6 400
lk (nm) ND
§ ND§ 200 6 10 120 6 50 130 6 40
nb – – – 5 6 2 9 6 3
Data at the lowest three concentrations of KLVFFK6 were analyzed using a linear semiﬂexible chain model, whereas at the highest two concentrations, the
branched structure model was assumed. ÆMæw, weight-average molecular mass; Lc, the contour length of ﬁbril in the semiﬂexible chain; Lc,a, the contour
length of one arm in the branched structure; lk, Kuhn statistical length; nb, the number of branches in the branched structure.
*All samples contained 140 mM of Ab.
yData were taken 21 h after dilution.
zData were taken 2 h after dilution.
§ND, not determined. Because Lc is shorter than lk, the ﬁbrils behave as rigid rods and lk cannot be determined.
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density of Ab aggregates in the presence of KLVFFK6 (Lowe
et al., 2001; Moss et al., 2003).
We wondered whether we could interpret our results in
light of recent ﬁndings about Ab aggregate structure reported
by the Tycko group (Tycko, 2003). Brieﬂy, using solid-state
NMR techniques, they proposed the following model: a),
each Ab molecule contains two b-strands (residues 13–24
and 30–40) separated by a bend (25–29); b), a double-layered
‘‘cross-b unit’’ is constructed from anAb dimer, with the two
strands in each Ab molecule belonging to separate b-sheets;
and c), a ‘‘protoﬁlament’’ contains two cross-b units laterally
assembled into a four-layered structure. The mass-per-unit
length (MPL) of a single cross-b unit was estimated at 9 kDa/
nm, andMPL of a protoﬁlament at 18 kDa/nm. Protoﬁlament
formation is hypothesized to be driven by hydrophobic
collapse occurring between the 30–40 strands in adjacent
cross-b units. Further lateral association of protoﬁlaments,
via hydrophobic and electrostatic interactions, is allowed by
the Tycko model. Atomic force microscopy studies from
other groups provide further evidence of the existence of
a mechanism for ﬁbril growth by lateral association (Harper
et al., 1997; Nichols et al., 2002).
We calculated MPL for our Ab aggregates from ÆMæw, Lc,
(Table 2) and the fraction of peptide that was aggregated
(Table 1). Average MPL was estimated at ;6 kDa/nm for
Ab alone, and increased up to ;20 kDa/nm at high
KLVFFK6:Ab ratio. These estimates are in the same range
as those of Tycko (2003), and suggest that the aggregated
species we observe are not highly laterally associated. In light
of the Tycko model, we speculate that, at no or low
KLVFFK6, the detected species (what we call ‘‘ﬁlaments’’)
are predominantly elongated cross-b units. As the KLVFFK6
dose increases, there is a shift toward lateral assembly of
cross-b units into ‘‘protoﬁlaments,’’ and further alignment of
‘‘protoﬁlaments’’ into ﬁbrils. (Our model does not allow for
a stable population of ‘‘protoﬁlaments’’; their stability re-
lative to elongated cross-b units and ﬁbrils may depend on
solvent conditions.) We propose that KLVFFK6 increases the
strength of the hydrophobic interaction, driving protoﬁlament
and ﬁbril formation. We have recently reported on a chemical
modiﬁcation of KLVFFK6 that increases solvent surface
tension and greatly accelerates Ab aggregation relative to
KLVFFK6 (Kim et al., 2003), in agreement with this
hypothesis. This result, together with those reported here, is
consistent with a speculation that this class of peptides drives
Ab aggregation via changes in solvent properties, therefore
strengthening hydrophobically driven lateral association.
Despite the dramatic effect of KLVFFK6 on lateral
association, very little (,10%) of the peptide, if any, was
actually incorporated into Ab ﬁbrils. Still, a peptide with
a nonhomologous recognition element, KLVIIK6, had no
effect on Ab aggregation (data not shown), indicating that
some binding between KLVFFK6 and Ab must occur. We
hypothesized that KLVFFK6 binds reversibly to m binding
sites on the ﬁlaments;
½ f 1m½P4½ f  Pm; (1)
where [ f] ¼ free ﬁlament concentration, [P] ¼ free
KLVFFK6 peptide concentration, and [ fPm] ¼ ﬁlament-
peptide complex concentration (all in mM). In the absence of
KLVFFK6, we modeled the kinetics of lateral association of
ﬁlaments as a third-order process (Pallitto and Murphy,
2001):
FIGURE 5 Measured average hydrodynamic diameter dsph (A) and
average scattering intensity Is(90) (B) of Ab aggregates for Ab alone
(s), KLVFFK6 1 Ab (1:10) (d), (1:1) (n), (2.5:1) (:), and (5:1) (h) are
shown along with model simulations (lines) generated using parameters
given in Table 3.
TABLE 3 Effect of KLVFFK6 on model parameters
Molar ratio (KLVFFK6:Ab)*
0:1 0.1:1 1:1 2.5:1 5:1
kn/kp
(108 mM5h1)
2.5 6 2.0 9 6 4 1.4 6 0.5 0.7 6 0.04 1.6 6 0.9
kla
(103 mM2h1)




13 6 6 7 6 2 1.0 6 0.1 1.6 6 0.2 2.4 6 0.8
Other parameters not shown here were set equal to previously determined
values (Pallitto and Murphy, 2001).
*All samples contained 140 mM of Ab.
ykij is calculated from dvﬁb as previously described (Pallitto and Murphy,
2001).
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d½F
dt
¼ kla½ f 3: (2)
Binding of KLVFFK6 changes ﬁlament-ﬁlament versus
ﬁlament-solvent energetics to favor ﬁlament-ﬁlament lateral
association. In the presence of KLVFFK6, we modeled
lateral association of ﬁlaments with and without bound
peptide also as a third-order process:
d½F#
dt
¼ k#la½ f s½ f  Pm3s; (3)




½ f  Pm3s½ f s
½ f 3 ;
or
log k#la ¼ constant1 log kla1 ð3 sÞlog ½ f  Pm½ f 
 
; (4)
where kla is the lateral association rate constant for Ab alone,
and k#la is the lateral association rate constant in the presence
of KLVFFK6 and is a function of the peptide’s concentration
and its afﬁnity for binding to ﬁlaments. Because [ f]total ¼ [ f]
1 [ fPm]:
log k#la ¼ constant1 log kla
1 ð3 sÞlog ½ f  Pm½ f total  ½ f  Pm
 
; (5)
where [ f]total ¼ total ﬁlament concentration (in mM). To
evaluate these hypotheses, we need to determine how [ fPm]
changes with total peptide concentration. We assumed that
KLVFFK6 binds to m identical and noninteracting sites on




¼ ½P½P1Kd ; (6)
where [Pb] ¼ concentration of peptide bound to ﬁlament.
Because ½Pb=m ¼ ½ f  Pm on average and [P]  [P]total as
described in Results, Eq. 5 is further reduced by combination
with Eq. 6:




We plotted log k#la vs. log [P]total from Table 3 and obtained
a slope of 3 s¼ 1.3, or s¼ 1.7. Because s, 3, this analysis
implies that only half of the ﬁlaments in a ﬁbril must contain
bound KLVFFK6 to render signiﬁcant change in lateral
association. Using Kd ; 40 mM for binding of KLVFFK6 to
Ab (Cairo et al., 2002), combined with our observations that
,10% of all KLVFFK6 is bound to Ab, and that the average
ﬁlament is a 120-mer (Tables 1 and 2), we estimate from Eq. 6
that m  50. Therefore .60% ((120  50)/120) of all Ab
molecules in a ﬁlament are protected, unable to bind to
KLVFFK6.
From our data, we were unable to ascertain whether
KLVFFK6 remained bound to ﬁbrils (‘‘stoichiometric’’
mode) or was released from ﬁbrils and available for another
round of binding to ﬁlaments (‘‘catalytic’’ mode). Equation 7
suggests that stronger afﬁnity (lower Kd) of peptide to Ab
leads to larger lateral association of ﬁlaments, as long as the
amount of peptide bound to ﬁlament is small relative to total
peptide concentration. In the catalytic mode, however, a very
strong afﬁnity of peptide binding to Ab ﬁlaments would
reduce the peptide’s effectiveness at increasing lateral as-
sociation. In other words, there would be an optimum binding
afﬁnity of peptide to Ab, if these peptides act catalytically
rather than stoichiometrically. With a panel of peptide
inhibitors, lower Kd correlated strongly with greater effect
on Ab aggregation and greater potency in inhibiting toxicity
(Cairo et al., 2002). However, in none of these peptides was
the binding afﬁnity strong enough to distinguish between
catalytic and stoichiometric modes of action.
The fact that the predominant effect of KLVFFK6 is to
accelerate lateral alignment, leading to a decrease in the
relative fraction of ﬁlament compared to ﬁbril, is consistent
with the hypothesis that intermediate species such as the
cross-b unit or the protoﬁlament are toxic (Kirkitadze et al.,
2002). This is demonstrated in Fig. 6, where we use the
kinetic model to calculate the ﬁlament and ﬁbril fraction as
a function of KLVFFK6 concentration. Previous work from
our group suggested that intermediate Ab species with highly
exposed hydrophobic patches interact most strongly with the
lipid bilayer and lead to changes in membrane ﬂuidity
(Kremer et al., 2000). Such changes in membrane physical
properties may produce harmful effects on cellular function-
ing. KLVFFK6 could reduce Ab toxicity by accelerating
burial of these hydrophobic patches and driving formation of
inert fully formed ﬁbrils.
This analysis demonstrates the utility of a detailed mathe-
matical model in interpreting the mode of action of putative
aggregation modiﬁers. Speciﬁcally, for KLVFFK6 we con-
cluded that 1), this inhibitor does not change the distribution
of Ab between amyloid and nonamyloid paths; 2), this
inhibitor affects most strongly the rate of lateral aggregation
ofAbﬁlaments into ﬁbrils; and 3), this inhibitor interacts with
aggregated, not monomeric, Ab, to enhance hydrophobically
driven association. Such an analysis can contribute in two
ways: ﬁrst, to develop testable hypotheses for the mechanism
of toxicity, and second, to suggest new design strategies in the
search for better inhibitors of Ab toxicity.
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